Health Library
April 13, 2026
Question on this topic? Get an instant answer from August.
Yes. Wegovy is a GLP-1 receptor agonist. Its active ingredient is semaglutide, which is a lab-made version of the GLP-1 hormone your gut releases after meals. You inject it once a week, and it works by boosting insulin, slowing digestion, and reducing appetite through same pathways your body's own GLP-1 uses.
What makes Wegovy different from other semaglutide products is its dose and its approved purpose. Wegovy is prescribed specifically for chronic weight management, not for diabetes. It is currently one of only two GLP-1 medications with FDA approval for that use.
Wegovy reduces your weight through two connected mechanisms.
The first is gastric emptying. Semaglutide slows how quickly food leaves your stomach. When food sits longer, your blood sugar rises more gradually after meals and you feel satisfied for a longer stretch. Portion sizes tend to shrink naturally because you simply don't feel hungry as fast.
The second is direct appetite suppression in brain. GLP-1 receptors in the hypothalamus respond to semaglutide by turning down hunger signals at neurological level. This is not willpower. It is chemistry. Your brain receives a sustained message that you have had enough, and urge to eat between meals drops.
Together, these two effects reduce daily calorie intake without requiring you to fight constant hunger. In clinical trials, patients on highest dose of Wegovy (2.4 mg weekly) lost an average of about 15% of their starting body weight over 68 weeks. That is a larger effect than what most other weight loss medications have achieved.
Wegovy and Ozempic contain exact same molecule: semaglutide. The difference is dosing and labeling.
Ozempic is approved for type 2 diabetes. Its doses top out at 2 mg per week. The primary goal is blood sugar control, and weight loss happens as a beneficial side effect.
Wegovy is approved for chronic weight management. Its target dose is 2.4 mg per week, higher than anything available under Ozempic label. It is prescribed for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea.
Same drug. Different dose. Different approved use. Different insurance pathway.
A doctor would not prescribe Ozempic "off-label" for weight loss when Wegovy exists a correct dose for that purpose. And insurance companies typically treat them as separate products with separate prior authorization requirements.
Zepbound is other FDA approved GLP 1 class drug for weight management, but it contains a different active ingredient: tirzepatide. Where Wegovy activates only GLP-1 receptor, Zepbound activates both GLP-1 and GIP receptors.
In clinical trials, tirzepatide (Zepbound) produced greater average weight loss than semaglutide (Wegovy) at comparable timepoints. Some patients o highest tirzepatide dose lost over 20% of their body weight. However, both drugs are effective, and right choice depends on your medical history, insurance coverage, and how your body responds.
If you are weighing the two options, your doctor can help you compare them based on your specific situation. Older GLP-1 drugs like Saxenda (liraglutide) are also still available for weight management, though they require daily injections rather than weekly.
The FDA approval covers adults with a BMI of 30 or higher. It also covers adults with a BMI of 27 or higher who have at least one weight-related medical condition. Those conditions include type 2 diabetes, hypertension, dyslipidemia (abnormal cholesterol or triglyceride levels), and obstructive sleep apnea.
In 2023, Wegovy also received FDA approval for reducing risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and either obesity or overweight. That was a meaningful expansion because it positioned semaglutide as a heart-protective medication, not just a weight loss drug.
Wegovy is not approved for children under 12. For adolescents aged 12 and older, there is a separate approval with adjusted dosing.
The side effect profile is similar to other GLP-1 drugs because mechanism is same.
Nausea is most common complaint, especially during first few weeks and after each dose increase. It happens because semaglutide slows your stomach. If you eat a full meal while your stomach is still working on last one, the discomfort can be noticeable.
Other common effects include vomiting, diarrhea, constipation, and abdominal pain. These typically settle down over time. The dosing schedule is designed to help with this. You start at 0.25 mg weekly and increase every four weeks until you reach maintenance dose of 2.4 mg. That gradual ramp gives your body time to adjust.
Less common but serious concerns include pancreatitis, gallbladder problems (more likely with extended use), and a precautionary thyroid warning from animal studies. Wegovy is contraindicated for anyone with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
For most people, yes. Research consistently shows that stopping semaglutide leads to weight regain. In one trial, patients who stopped after reaching their weight loss goal regained roughly two-thirds of lost weight within a year.
That is not a failure of discipline. It is biology. Your body has hormonal and neurological systems that actively defend a higher weight set point. GLP-1 drugs work with those systems. When drug stops, those systems push back.
Doctors generally frame Wegovy as a long-term treatment, similar to blood pressure or cholesterol medication. Pairing it with sustainable dietary and lifestyle changes can support better outcomes, but medication itself is typically part of the plan for foreseeable future.
If you and your doctor decide to taper off, doing it gradually with medical supervision is recommended approach.
Get clear medical guidance
on symptoms, medications, and lab reports.